EP 2509630 A4 20130717 - DELIVERY SYSTEM FOR CYTOTOXIC DRUGS BY BISPECIFIC ANTIBODY PRETARGETING
Title (en)
DELIVERY SYSTEM FOR CYTOTOXIC DRUGS BY BISPECIFIC ANTIBODY PRETARGETING
Title (de)
SYSTEM ZUR VERARBEITUNG ZYTOTOXISCHER HEILMITTEL DURCH BISPEZIFISCHE ANTIKÖRPER-ANZIELUNG
Title (fr)
SYSTÈME D'ADMINISTRATION POUR MÉDICAMENTS CYTOTOXIQUES PAR PRÉ-CIBLAGE D'ANTICORPS BISPÉCIFIQUE
Publication
Application
Priority
- US 26799809 P 20091209
- US 64414609 A 20091222
- US 73178110 A 20100325
- US 75264910 A 20100401
- US 75474010 A 20100406
- US 86982310 A 20100827
- US 87134510 A 20100830
- US 91551510 A 20101029
- US 94953610 A 20101118
- US 2010059686 W 20101209
Abstract (en)
[origin: WO2011072124A1] The present invention relates to methods and compositions for pretargeting delivery of therapeutic agents. In preferred embodiments, the pretargeting method comprises: a) administering a bispecific antibody with a first binding site for a disease-associated antigen and a hapten on a targetable construct; b) administering a targetable construct comprising at least one therapeutic agent. In preferred embodiments, the bispecific antibody is made by the dock-and-lock (DNL) technique. In a more preferred embodiment, the targetable construct comprises one or more SN-38 moieties.
IPC 8 full level
A61K 39/395 (2006.01); A61K 47/48 (2006.01); A61P 35/00 (2006.01); C07K 14/52 (2006.01); C07K 14/56 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/44 (2006.01); C07K 16/46 (2006.01)
CPC (source: EP)
A61K 47/6879 (2017.07); A61K 47/6897 (2017.07); A61P 35/00 (2017.12); B82Y 5/00 (2013.01); C07K 16/2803 (2013.01); C07K 16/2833 (2013.01); C07K 16/2863 (2013.01); C07K 16/2887 (2013.01); C07K 16/30 (2013.01); C07K 16/3007 (2013.01); C07K 16/303 (2013.01); C07K 16/3092 (2013.01); C07K 16/44 (2013.01); C07K 2317/31 (2013.01); C07K 2317/626 (2013.01); C07K 2317/73 (2013.01)
Citation (search report)
- [XI] WO 2006107786 A2 20061012 - IBC PHARMACEUTICALS INC [US], et al
- [XI] WO 2007075270 A2 20070705 - IBC PHARMACEUTICALS INC [US], et al
- [XI] US 2009191225 A1 20090730 - CHANG CHIEN-HSING [US], et al
- [Y] WO 2004094613 A2 20041104 - IBC PHARMACEUTICALS [US], et al
- [Y] US 2003198595 A1 20031023 - GOLDENBERG DAVID M [US], et al
- [A] WO 2007046893 A2 20070426 - IBC PHARMACEUTICALS INC [US], et al
- [A] WO 2007134037 A2 20071122 - IMMUNONOMEDICS INC [US], et al
- [A] US 2009202487 A1 20090813 - CHANG CHIEN-HSING [US], et al
- [A] WO 2009126558 A1 20091015 - IBC PHARMACEUTICALS INC [US], et al
- [A] WO 2009055653 A1 20090430 - IBC PHARMACEUTICALS INC [US], et al
- [A] US 2006154330 A1 20060713 - KLUSSMANN ENNO [DE], et al
- [A] US 2003232420 A1 20031218 - BRAUN ANDREAS [US], et al
- [A] US 2002040130 A1 20020404 - BRAUN ANDREAS [US]
- [A] D. M. GOLDENBERG ET AL: "Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting", THE JOURNAL OF NUCLEAR MEDICINE, vol. 49, no. 1, 1 January 2008 (2008-01-01), pages 158 - 163, XP055028152, ISSN: 0161-5505, DOI: 10.2967/jnumed.107.046185
- See references of WO 2011072124A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2011072124 A1 20110616; CA 2782398 A1 20110616; CA 2782398 C 20170926; CN 102665757 A 20120912; EP 2509630 A1 20121017; EP 2509630 A4 20130717
DOCDB simple family (application)
US 2010059686 W 20101209; CA 2782398 A 20101209; CN 201080052649 A 20101209; EP 10836680 A 20101209